Promoting Immunotherapy Efficacy With Low-Dose Liver RT

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Jordan Kharofa
Study ID
NCT07225036
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LD-LRT — RADIATION
    Low-dose radiation to the liver the week prior to Cycles 1, 2 and 3 of standard of care immunotherapy treatment.

Study Details

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

Key Dates

Start date
Dec 15, 2025
Status verified
Feb 2026
Primary completion
Jun 15, 2027
Completion
Dec 15, 2029

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LD-LRT
    Low-dose radiation to the liver the week prior to Cycles 1, 2 and 3 of systemic treatment.

Primary Outcome Measure

Progression free survival (PFS) measured by 6-month PFS for each cohort compared separately to historical trials with an effect size goal of 25% improvement in 6-month PFS [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Cincinnati Medical CenterCincinnatiOhio45219
UCCC CTO
[email protected]
513-584-7698
Jordan Kharofa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cincinnati, OH

By condition
MelanomaLung cancer
By specialty
OncologySkin cancerDermatologyLung oncologyLung disease
By research site
University of Cincinnati Medical Center· Cincinnati, OH

Related Studies